Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01878513 · ClinicalTrials.gov registry record · NA
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis
A NA study, sponsored by Northwell Health.
- Completed
- Registry status
- NA
- Development phase
- 88
- Enrollment target
NCT01878513: Completed NA study, sponsored by Northwell Health.
NCT01878513 is a NA study that has completed, run by Northwell Health. The registered enrollment target is 88 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01878513, a NA study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 88 participants
- Enrollment target
Study Summary
The aim of the study is to examine whether determining treatment strategies based upon Cytochrome P450 2D6 (CYP2D6) genotype will improve drug response rates and clinical outcome in patients with psychosis. The investigators predict that prospectively testing CYP2D6 genotype and using this information to treat psychotic patients with risperidone will improve clinical outcomes. Specifically, CYP2D6 poor metabolizers who are treated with low dose and slow titration of risperidone will do better than those who are treated with usual dose and titration approach in terms of rates of side effects and clinical improvement.
Primary Outcome
Scores on: 1. Schedule for Assessment of Negative Symptoms (SANS) 2. Brief Psychiatric Rating Scale (BPRS) 3. Global Impression - Improvement scale (CGI-I)
Interventions
- DRUG risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2009-09-23 |
| Est. Completion | 2018-07-31 |
| Phase | NA |
What the finished NCT01878513 record still lists
NCT01878513 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which risperidone is the first listed.
NCT01878513 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01878513 about?
NCT01878513 is a clinical study titled "Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis". The aim of the study is to examine whether determining treatment strategies based upon Cytochrome P450 2D6 (CYP2D6) genotype will improve drug response rates and clinical outcome in patients with psychosis. The investigators predict that prospectively testing CYP2D6 genotype and using this informat...
What is the current status of trial NCT01878513?
This trial is currently completed. It is a NA study. The enrollment target is 88 participants. The study started on 2009-09-23. Estimated completion is 2018-07-31.
What interventions are being tested in trial NCT01878513?
The interventions under investigation include: risperidone (DRUG).
Who is sponsoring clinical trial NCT01878513?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01878513's enrollment target sits among peer trials
88 972nd of 2000 higher than 1,027 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI